# Phase I/II Combination With Irinotecan- Erbitux

> **NCT00594984** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 38 (actual)

## Conditions studied

- Metastatic Colorectal Cancer (MCRC)

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Irinotecan
- **DRUG:** Brivanib
- **DRUG:** Brivanib
- **DRUG:** Brivanib Placebo

## Key facts

- **NCT ID:** NCT00594984
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00594984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00594984, "Phase I/II Combination With Irinotecan- Erbitux". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00594984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*